Lilly Gets FDA Approval for Eczema Drug Ebglyss - Eli Lilly ( NYSE:LLY ) , Biogen ( NASDAQ:BIIB )
Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss ( lebrikizumab ) for treating moderate-to-severe atopic dermatitis, also called eczema.
| Ticker |
Sentiment |
Impact |
|
LLY
|
Somewhat Bullish
|
57 %
|
|
PFE
|
Bullish
|
28 %
|
|
BIIB
|
Somewhat Bullish
|
11 %
|
